86711-45-7 Usage
Description
(E)-3-(4-(benzyloxy)phenyl)-1-(p-tolyl)prop-2-en-1-one is a chemical compound characterized by its molecular formula C23H21O2. It is a yellow crystalline powder known for its trans configuration and the presence of a benzyl ether group, a p-tolyl group, and a propenone group. (E)-3-(4-(benzyloxy)phenyl)-1-(p-tolyl)prop-2-en-1-one is widely recognized for its role in the synthesis of pharmaceuticals and organic compounds, as well as its potential therapeutic properties and applications in various pharmacological fields.
Uses
Used in Pharmaceutical Synthesis:
(E)-3-(4-(benzyloxy)phenyl)-1-(p-tolyl)prop-2-en-1-one is used as a starting material in the pharmaceutical industry for the synthesis of various organic compounds. Its unique structure and functional groups make it a valuable building block in the development of new drugs and pharmaceutical agents.
Used in Organic Synthesis:
In the field of organic chemistry, (E)-3-(4-(benzyloxy)phenyl)-1-(p-tolyl)prop-2-en-1-one serves as a key intermediate in the synthesis of a wide range of biologically active molecules. Its versatility and reactivity contribute to the creation of complex organic structures with potential applications in various industries.
Used in Research and Development:
(E)-3-(4-(benzyloxy)phenyl)-1-(p-tolyl)prop-2-en-1-one is also utilized in research and development for the exploration of its potential therapeutic properties. Studies have shown promising results in various pharmacological applications, making it a valuable compound for further investigation and development in the medical field.
Used in Drug Design and Development:
(E)-3-(4-(benzyloxy)phenyl)-1-(p-tolyl)prop-2-en-1-one is used as a building block in drug design and development, particularly for the creation of novel biologically active molecules with potential therapeutic applications. Its unique structure and functional groups allow for the development of innovative drugs with improved efficacy and selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 86711-45-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,7,1 and 1 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 86711-45:
(7*8)+(6*6)+(5*7)+(4*1)+(3*1)+(2*4)+(1*5)=147
147 % 10 = 7
So 86711-45-7 is a valid CAS Registry Number.
86711-45-7Relevant articles and documents
Chalcones and bis-chalcones: As potential α-amylase inhibitors; synthesis, in vitro screening, and molecular modelling studies
Tajudeen Bale, Adebayo,Mohammed Khan, Khalid,Salar, Uzma,Chigurupati, Sridevi,Fasina, Tolulope,Ali, Farman,Kanwal,Wadood, Abdul,Taha, Muhammad,Sekhar Nanda, Sitanshu,Ghufran, Mehreen,Perveen, Shahnaz
, p. 179 - 189 (2018)
Despite of a diverse range of biological activities associated with chalcones and bis-chalcones, they are still neglected by the medicinal chemist for their possible α-amylase inhibitory activity. So, the current study is based on the evaluation of this c
Antiproliferative effects of chalcones on T cell acute lymphoblastic leukemia-derived cells: Role of PKCβ
Corsini, Emanuela,Facchetti, Giorgio,Esposito, Sara,Maddalon, Ambra,Rimoldi, Isabella,Christodoulou, Michael S.
, (2020/05/16)
In this study, a series of 20 chalcone derivatives was synthesized, and their antiproliferative activity was tested against the human T cell acute lymphoblastic leukemia-derived cell line, CCRF-CEM. On the basis of the structural features of the most active compounds, a new library of chalcone derivatives, according to the structure–activity relationship design, was synthesized, and their antiproliferative activity was tested against the same cancer cell line. Furthermore, four of these derivatives (compounds 3, 4, 8, 28), based on lower IC50 values (between 6.1 and 8.9 μM), were selected for further investigation regarding the modulation of the protein expression of RACK1 (receptor for activated C kinase), protein kinase C (PKC)α and PKCβ, and their action on the cell cycle level. The cell cycle analysis indicated a block in the G0/G1 phase for all four compounds, with a statistically significant decrease in the percentage of cells in the S phase, with no indication of apoptosis (sub-G0/G1 phase). Compounds 4 and 8 showed a statistically significant reduction in the expression of PKCα and an increase in PKCβ, which together with the demonstration of an antiproliferative role of PKCβ, as assessed by treating cells with a selective PKCβ activator, indicated that the observed antiproliferative effect is likely to be mediated through PKCβ induction.
